Background-Evaluation of novel cellular therapies in large-animal models and patients is currently hampered by the lack of imaging approaches that allow for long-term monitoring of viable transplanted cells. In this study, sodium iodide symporter (NIS) transgene imaging was evaluated as an approach to follow in vivo survival, engraftment, and distribution of human-induced pluripotent stem cell (hiPSC) derivatives in a pig model of myocardial infarction. Methods and Results-Transgenic hiPSC lines stably expressing a fluorescent reporter and NIS (NIS pos -hiPSCs) were established. Iodide uptake, efflux, and viability of NIS
has been achieved concerning scalable cell production 5, 6 and more efficient and specific differentiation into cell types of interest. 7 
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However, there are still major hurdles and risks to overcome with regard to PSC-based heart repair. These include safety risks, especially the potential of teratoma and tumor formation, 2 low cell retention and engraftment rates, 8 -11 and the general question of whether engraftment of hiPSCs after simple intramyocardial cell injection leads to formation of functional tissue, such as de novo vasculature or myocardium, and results in significant clinical benefits. 12 Although some of these issues can be addressed in vitro or in appropriate small-animal models, others will require exploration in large-animal models, which are more similar to humans. 13 Transplanted human cardiomyocytes, for example, are unlikely to fully functionally integrate with rodent myocardium because of highly dissimilar beating rates. 11 Therefore, meaningful assessment of human cells for heart repair must be demonstrated in large-animal models such as dogs, pigs, or monkeys. 13 Clearly, advanced imaging technologies allowing for longitudinal tracking of cellular grafts and ideally enabling monitoring of donor cell survival, proliferation, distribution, or even differentiation are crucial for (pre)clinical evaluation of novel cellbased therapeutics. 14 At present, transgene-based imaging approaches that fulfill these requirements are mainly restricted to far-red fluorescence reporters or photon-emitting technologies, in particular those based on luciferase expression. Unfortunately, limited tissue penetration restricts application of these technologies to small-animal models only. 15 Most previous large-animal studies applied magnetic resonance imaging technology to detect nanoparticle-labeled cells. 16 The main disadvantage of this approach is the inability to discriminate vital donor cells from nanoparticle-loaded cell debris or the recipient's cells such as macrophages, which can actively incorporate cell debris and released nanoparticles by phagocytosis. 16 In other studies, direct radionuclide labeling of cells was performed ( Tc-hexamethylprophylene amine oxine). 16 Limitations of the latter techniques include isotope half-time-and label-retention-dependent loss of signal strength. 16 In addition, direct labeling strategies with nanoparticles or radionuclides, particularly for In 111 , have been reported to affect (stem) cell vitality. 16 In a first pilot study to overcome these critical drawbacks, herpes simplex virus thymidine kinase-mediated phosphorylation of [ 18 F]FHBG was evaluated as a transgene-based imaging approach in large animals, 17, 18 but detection of transplanted cells was reported several hours after cell injection only.
Another promising approach has been developed recently, 19 which permits detection of viable transplanted cells by positron emission tomography (PET) or single photon emission computed tomography (SPECT) after iodide ( 123 I) or 99m Tc radiotracer administration. This technology relies on the expression of a transgenic sodium iodide symporter (NIS) 20 in transplanted donor cells. Physiological expression of NIS in the adult organism is restricted to the thyroid, stomach, choroids plexus, and salivary gland and is not detectable in limbs, brain, or other internal organs such as the heart. 20 NIS-mediated iodide accumulation in the thyroid is an active transport process that occurs at the basolateral plasma membrane of the thyroid follicular cells against the iodide electrochemical gradient stimulated by thyroidstimulating hormone and can be specifically inhibited by perchlorate. Clinically, NIS expression provides the basis for the effective diagnostic of thyroid cancer and its metastases by iodide isotope administration. 20 The technology provides important advantages with respect to clinical application for longitudinal tracking of stem cell grafts. This includes the lack of immunogenicity of the human NIS transgene and the fact that SPECT scanning of radiotracers such as 99m Tc and 123 I is widely available at relatively low cost and is approved by responsible regulatory authorities such as the Food and Drug Administration. Moreover, recent progress in quantification of tracer signals with the use of clinical SPECT systems 21 emphasizes the potential of this approach for tracking cellular transplants in large animals and patients. To date, however, the strategy was evaluated only in a small-animal model focused on detection of acute cell retention after administration of cardiac derived stem cells. 19 In the present study, we demonstrate the applicability of this technology for in vivo monitoring of cellular grafts in a pig model of myocardial infarction. SPECT/computed tomographic (CT) imaging results revealed successful in vivo donor cell labeling by intracoronary iodide administration 5 days or 12/15 weeks after intramyocardial cell transplantation. These data were confirmed by immunohistochemistry on harvested tissue, providing unequivocal evidence for long-term survival, engraftment, and differentiation of transplanted hiPSC derivatives.
Methods

Culture of hiPSCs
Conventional culture of hiPSCs was performed as described previously. 1 Mass cell generation of NIS transgenic hiPSCs (NIS pos -hiPSCs) in suspension cultures was performed as described previously. 5, 6 Generation of NIS
pos -hiPSC Lines
See the online-only Data Supplement for details of NIS pos -hiPSC lines.
Characterization of NIS pos -hiPSCs
See Figure 1 and the online-only Data Supplement for details.
Iodide Uptake and Efflux
See the online-only Data Supplement for details.
Ex Vivo Cardiac SPECT/CT Imaging
For assessing the SPECT/CT detection limit in terms of prelabeled NIS pos -hiPSCs, cells were incubated for 90 minutes with 1 MBq 123 I per 1ϫ10 6 cells. After vigorous washing, serial cell dilutions comprising a total of 1ϫ10 4 , 1ϫ10 5 , 5ϫ10 5 , 1ϫ10 6 , 3ϫ10 6 , 6ϫ10 6 , or 1.2ϫ10 7 labeled cells were injected into the lateral and septal walls of the left ventricle. The 123 I signal was visualized through a dual-detector hybrid SPECT/CT scanner (Infinia Hawkeye, GE Healthcare). To mimic in vivo imaging, heart-derived 123 I signals were recorded through a dissected pig chest that was placed above the heart to mimic signal attenuation.
Large-Animal Model
Female Landrace pigs (Large White Duroc, Sidler, Zurich, Switzerland; nϭ13; weight, 25-30 kg; aged 8 -10 weeks) were investigated in the present study. Animals were immunosuppressed with cyclosporine A (Novartis Pharmaceuticals, East Hanover, NJ; 10 mg/kg body wt daily) and prednisolone (Pfizer, Zurich, Switzerland; 2.5 mg/kg body wt daily) starting 5 days before hiPSC transplantation until animals were euthanized. Furthermore, all animals received 2ϫ400 mg/d dronedarone at the first preoperative and operative day and 2ϫ200 mg/d from the first postoperative day until the end of the study. All procedures were approved by the responsible local authorities and performed according to the Guide to the Care and Use of Experimental Animals published by the US National Institutes of Health (National Institutes of Health publication 85-23, reviewed 1996) . A detailed description of the study design is shown in Figure 2 .
Induction of Myocardial Infarction
Myocardial infarction was created by inflating the balloon for 180 minutes in the mid segment of the left anterior descending coronary artery, followed by reperfusion. See the online-only Data Supplement for details.
Electromechanical Mapping
Three-dimensional NOGA mapping (Biologics Delivery Systems, Biosense Webster, Johnson & Johnson, Irwindale, CA) was performed 10Ϯ2 days after induction of myocardial infarction to assess electrophysiological tissue viability patterns and wall motion abnormalities. The catheter was placed through the right carotid sheath across the aortic valve into the left ventricle. By navigating the catheter along the endocardium, the local intracardiac electrogram together with the wall motion was recorded from its tip at multiple endocardial sites, and detailed 3-dimensional electromechanical maps of the left ventricle were generated. The unipolar voltage values were color coded (visualizing infarct zones as red and viable tissue as green to purple) and superimposed on the 3-dimensional geometry of the map. NOGA mapping and injections were performed as described previously. 22 pos -hiPSC aggregates derived from suspension culture and the respective isotope control. For immunostaining, an anti-green fluorescent protein antibody was used, which cross-reacts with the yellow green fluorescent protein variant Venus. Notably, fixation and immunohistochemistry treatments lead to an apparently cytoplasmic Venus-specific staining, which is in contrast to the direct Venus fluorescence in viable cells that is strictly restricted to the nuclear membrane, as shown in C. E, Kinetics of 125 I uptake by NIS pos -hiPSCs (clone 6), inhibition by 100 mol/L perchlorate, and NIS neg -hiPSC controls (meanϮSEM, triplicate measurements). Iodide uptake reached a steady state within 90 minutes with a maximum concentration of Ϸ100-fold above background in negative controls. 125 I accumulation in NIS poshiPSCs was completely abolished by perchlorate, suggesting specificity of the signal. F, Kinetics of iodide retention in NIS pos -hiPSCs (meanϮSEM, triplicate measurements). hCBiPS indicates human cord blood iPS. 
Intramyocardial Cell Injections
CT Angiography
For cardiac CT angiography, 1 mL/kg body wt iodixanol (Visipaque 320 mg/mL; GE Healthcare, Bucks, UK) at a flow rate of 4 to 5 mL/s followed by 50 mL saline solution was injected into the ear vein via a 20-gauge catheter. All scans were performed with the 64-detector CT component (LightSpeed VCT, GE Healthcare) of a SPECT/CT scanner with prospective ECG triggering, as established and described in detail previously. 23 Images were analyzed on an external workstation (AW 4; GE Healthcare).
Full-body CT scanning was performed on the same CT scanner with the use of 100 mL iodixanol.
SPECT Imaging
For assessment of myocardial perfusion, 99m TC (10 MBq/kg) was injected into the ear vein, and images were acquired over 5 minutes on the SPECT part of a hybrid SPECT/CT scanner (Discovery NM CT 570c, GE Healthcare) integrating a 64-slice CT device and a cadmium-zinc-telluride gamma camera. The cadmium-zinc-telluride camera has been extensively described recently. 24, 25 Briefly, it is a gamma detector with a pinhole collimator and 19 stationary detector modules positioned around the chest. For perfusion imaging, a symmetrical energy window at 140 keV (Ϯ5%) was used, and for dual peak acquisition with 123 I, a window at 159 keV (Ϯ5%) was added.
For mid-term (5 days after transplantation) and long-term (12-15 weeks after transplantation) detection of transplanted hiPSCs, we performed intracoronary injection of 123 I into each main coronary artery (left anterior descending, left circumflex, right coronary arteries) with the use of an over-the-wire balloon catheter during 3 coronary occlusions, each lasting 2 to 3 minutes. Between occlusions, the coronary artery was reperfused for 2 minutes. Afterward, animals underwent SPECT/CT imaging as described above.
See Figure II in the online-only Data Supplement for details.
(Immuno)Histological Analysis
See details in the online-only Data Supplement.
Results
Functional NIS Expression in Transgenic hiPSC Clones
hiPSCs (clone hCBiPSC2) 1 were cotransfected with the bicistronic vector pCAG_rNIS_IRES2_Venus_nucmem (Figure 1A) and the plasmid ␣MHCneoPGKhygro, 26 enabling selection of hygromycin-resistant transgenic cell clones. Six independent Venus pos clones (designated rNIS clones 1, 2, 4, 5, 6, 7) were analyzed for stability of transgene expression. Flow cytometry and fluorescence microscopy revealed robust and stable Venus expression for up to 23 passages with line-specific variations ( Figure 1B and 1C) . Venus-specific immunohistological assessment was also performed on paraffin sections of suspension culture-derived cell aggregates and differentiated cells in embryoid bodies. In contrast to the expected Venus fluorescence signal in the nucleus of viable cells ( Figure 1C ), cytoplasmic staining was noted after fixation and immunohistochemistry ( Figure 1D, left) ; however, staining specificity was proven by isotype ( Figure 1D I accumulation was Ϸ100 times higher than for nontransgenic hiPSC control cells ( Figure 1E ). Importantly, iodide uptake was completely blocked by the specific NIS inhibitor perchlorate. Typically, the majority of was detected through a dissected pig chest that had been placed above the heart to mimic signal attenuation in vivo. On the basis of these results, 5ϫ10 7 prelabeled NIS pos -hiPSCs were subsequently applied in vivo per injection area with a hypothetical detection threshold of Ϸ2% persistent cells. hiPSCs or 5ϫ10 7 hiPSCs coadministered with 5ϫ10 7 human MSCs, respectively, per injection area), intensive 123 I signals were detected by SPECT/CT imaging in the septal and lateral walls of the left ventricle, corresponding exactly to the injection site as recorded by NOGA mapping. As expected, 123 I-treated control cells injected into a separate region of the same heart did not result in a detectable SPECT signal (Figure 4, line 3) . Notably, MSC coadministration considerably increased signal intensity, suggesting improved hiPSC retention in the myocardium after transplantation (Figure 4 and Video I in the online-only Data Supplement). The signal intensity was highest in the first hour after cell transplantation and diminished successively. At 3 to 5 hours after injection, signal intensity was substantially reduced ( Figure VI 
Long-Term Detection of Engrafted NIS pos -hiPSC Derivatives for up to 15 weeks by SPECT/CT Imaging After Intracoronary Iodide Administration
For detection of transplanted NIS pos -hiPSC derivatives at 5 days and 12 to 15 weeks after intramyocardial cell injection, 123 I was infused by intracoronary injection into the left anterior descending, left circumflex, and right coronary arteries. One hour after tracer injection, the resulting 123 I signals were assessed. As expected, on SPECT/CT scanning, a very strong uptake was observed in the thyroid, whereas a weaker uptake was detected in the stomach (data not shown). Interestingly, in the heart, 123 I signals were detected exclusively in regions where NIS pos -hiPSCs had been cotransplanted with human MSCs (Figure 5 ). In independent hearts, 123 I accumulation was detected either in the lateral heart region or in the septal left ventricular wall, always correlating with the area of NIS pos -hiPSC/MSC coinjection. In contrast, no After SPECT/CT, hearts were euthanized for tissue sample analysis. In correlation with SPECT/CT imaging and NOGA mapping of myocardial infarction, histological analyses of respective heart regions (collected 5 days and 15 weeks after cell transplantation) revealed typical signs of infarction and subsequent fibrosis, including widespread replacement of myocardium by loose to densely arranged cells with fibroblast 
Discussion
The availability of transgene-based imaging technologies in large animals that enable nontoxic, specific, sensitive, non- invasive, and serial long-term imaging of viable grafts is of utmost importance for preclinical evaluation of stem cellbased therapies.
In the present study, we have established a reporter gene approach that enables in vivo monitoring of long-term survival of hiPSC derivatives in a pig model of myocardial infarction. Notably, this is the first report demonstrating the feasibility of repeated longitudinal in vivo imaging of cell viability, proliferation, and tissue distribution of cellular grafts in internal organs of large animals.
Similar to luciferase imaging in small animals, viable cells expressing NIS are able to accumulate 123 I and to evoke a detectable SPECT signal, thereby preventing false-positive detection of dead cells, cellular debris-bound label, or phagocytosing macrophages. Although the ratio of the intensity of the specific 123 I signal in our NIS pos -hiPSCs compared with NIS neg -hiPSCs as determined in vitro is lower than the typical signal-to-background ratio in the case of luciferase reporter systems, long-term surviving NIS pos -hiPSC derivatives evoked a 123 I signal of considerable intensity in the areas of intramyocardial cell injection. This may be explained by the relatively low absorption of the 123 I signal through soft and hard tissue and is in contrast to the very limited tissue penetration of luciferin-emitted light, which, even in small animals with low tissue thickness, leads to significant loss of signal.
Ex vivo injection of
123 I-labeled NIS pos -hiPSCs revealed a detection limit of Ϸ1ϫ10 5 cells in isolated pig hearts. Because 123 I signals were recorded through an isolated pig chest, one can expect signal intensities in vivo in the same range as those detected in hearts assessed ex vivo. Although not directly comparable, because (1) lentiviral vectors and another tracing approach were used; (2) another stem cell type, namely, cardiac stem cells, was applied; and (3) signal retention through pig chest is slightly different from retention through rat chest, the determined detection limit is in the same range as for cell transplantation into rat hearts. Here, Terrovitis et al 19 estimated 1.5ϫ10 5 as the minimal detectable cell number. Further advantages of human NIS-SPECT versus herpes simplex virus thymidine kinase-PET imaging are wide availability of the necessary tracers, lack of need for specialized radiosynthesis facilities, and lack of immunogenicity of the human NIS, which may be of critical importance for long-term monitoring in particular.
Obviously, SPECT imaging of NIS-expressing cell grafts has limitations. As is the case with every in vivo imaging approach, there is a detection limit in terms of a minimal detectable number of cells. Certainly, we cannot exclude distribution of single undifferentiated or differentiated hiPSC derivatives to other organs. Indeed, only if a critical number of cells accumulates or is reached as a result of local prolifera- tion, or the minimal detection limit at a specific site is achieved, can NIS-expressing engrafted cells be detected. Nevertheless, in our experiments, we were not able to detect any 123 I signals outside the heart despite the naturally NIS-expressing tissue sites. Autopsies of the euthanized animals 12 to 15 weeks after cell infusion confirmed these results and did not reveal any sign of tumor or teratoma formation. Together with the absence of OCT4 pos cells 12 to 15 weeks after cell transplantation, as analyzed by immunohistochemistry, this raises the question of whether the high incidence of teratomas observed in immunoincompetent mice is actually indicative of clinical applications or is rather an artifact of species incompatibilities that prevent natural control of cell proliferation in the specific tissue niches. Another potential explanation for the obvious absence of undifferentiated cells and the observed parallel persistence of differentiated vascular NIS pos -hiPSC derivatives might be the applied immunosuppressive protocol consisting of relatively high doses of cyclosporine A and prednisolone. In general, the long-term persistence of hiPSCderived endothelial cells indicates the efficacy of our immunosuppressive protocol, at least in terms of T-cell reactivity toward differentiated iPSC derivatives. However, there is evidence that cyclosporine A is not effective toward natural killer cells, 27 which might lead to selective natural killer cell-based erasure of undifferentiated PSCs. 28 In the case of prednisolone, recent data suggest that inhibition of natural killer cells depends on the mode of activation, thereby indicating that prednisolone treatment might also not fully prevent natural killer-mediated killing of undifferentiated hiPSCs. 29 Another limitation of this imaging technology is the physiological expression of NIS in the thyroid, stomach, choroid plexus, and salivary gland. Because the signals from these organs are strong, they may cover up weak signals from adjacent organs. For instance, although it does not pose a problem in larger animals such as the pig, the strong thyroid signal may interfere with close-by cardiac tracer signals in mice. In addition, the stomach background signal may interfere with tracer signals in the upper abdomen.
Of course, there is room for further improvement. Higher levels of NIS pos expression in optimized vector systems and selected stable cell clones may lead to further increase of 123 I accumulation compared with NIS neg control cells. In addition, we currently do not know whether potential silencing effects during in vivo differentiation of the transplanted NIS poshiPSCs may have diminished NIS expression in our experiments and whether expression systems with reduced silencing can lead to further increase of the 123 I signal. As mentioned above, immunohistochemical staining of myocardial tissue sections harvested 5 days and 12 to 15 weeks after cell application showed no OCT4 pos cells in the areas of previous cell infusion. Instead, Venus pos NIS poshiPSC derivatives with endothelial phenotype were detected, which contributed to the intramyocardial vasculature. Notably, the utilized CAG promoter-driven NIS does not allow following differentiation events through SPECT imaging. However, this could be realized by placing NIS under the control of cell type-specific promoters, for instance, the OCT4 promoter 5 or the cardiomyocyte-specific ␣-myosin heavy chain promoter. 30 Of importance for future clinical application of this technology will be the use of well-characterized transgenic cell clones with defined transgene integration through zinc finger or transcription activator-like effector (TALE) nuclease, 31 for instance, in safe harbor sites such as adeno-associated virus integration site 1, 31 thereby diminishing risks of insertional mutagenesis and carcinogenesis. Importantly, it must be assessed whether the required level of radiation can be reduced: Although the applied 123 I dose is on a level similar to that clinically applied for standard tumor therapies, it is far higher than for routine thyroid diagnostics, thereby prohibiting clinical application of the developed approach at this stage. Furthermore, and although the conducted minimal invasive cell application by intramyocardial hiPSC injection is of high clinical relevance, it must be evaluated whether similar or even higher sensitivities and signal-to-noise ratios can be obtained in case of global tracer delivery (eg, through the ear veins of the pig).
As a first application of the established technology for SPECT imaging of transgenic NIS expression, we have addressed the common problem of low cell survival and retention rates after cell transplantation. 8 -10 Typically, after intramyocardial cell infusion, the majority of donor cells are directly flushed back through the injection channel 10, 32 or do not survive the initial phase after transplantation. 9 To address this problem, Laflamme et al 8 recently described a novel prosurvival cocktail that can dramatically increase engraftment of transplanted human embryonic stem cell-derived cardiomyocytes in an athymic rat model. We have now investigated whether cotransplantation of human MSCs that release antiapoptotic factors 33 and express immunomodulatory properties 34 may improve the survival and engraftment of transplanted NIS pos -hiPSCs after xenotransplantation into pigs. Interestingly, SPECT imaging suggested a positive effect of the cotransplanted human MSCs even at 3 hours after cell infusion, showing a markedly stronger tracer uptake at the sites where NIS pos -hiPSCs had been cotransplanted with human MSCs than at the injection sites of pure NIS pos -hiPSCs. It is questionable whether this very early phenomenon can be explained through antiapoptotic effects. It is more likely that other factors, including MSC-mediated increased cell aggregation, which may favor engraftment and diminish the flushing out of transplanted cells, are responsible for this effect. However, in the mid and long terms (5 days and 12-15 weeks), NIS pos -hiPSCs could be detected exclusively at the site of coinjection, indicating an additional profound effect on long-term engraftment of NIS pos -hiPSCs. Certainly, deciphering the underlying mechanisms will require extensive additional investigations but will be of utmost importance to optimize MSC-supported survival of hiPSC derivatives.
Conclusions
This is the first study demonstrating the usefulness of the NIS for serial long-term tracking of survival, engraftment, and distribution of cellular grafts in a large-animal model in which SPECT/CT imaging was used. Moreover, for the first time we demonstrate long-term survival and differentiation of hiPSCs in a preclinical pig model of myocardial infarction. The applied 3-dimensional hybrid imaging protocol enables combined assessment of cardiac anatomy and myocardial perfusion and monitoring of donor cell survival, proliferation, and distribution within 1 imaging modality.
